Table 2.
Changes in Metabolic and Hemodynamic Parameter
| DAPA (n = 36) | Placebo (n = 36) | P | |
|---|---|---|---|
| Weight, kg | |||
| Baseline | 76.18 ± 14.10 | 79.40 ± 14.59 | 0.352 |
| Week 12 | 75.21 ± 11.89 | 80.96 ± 15.72 | 0.092 |
| Change | –1.05 ± 15.71 | 1.76 ± 18.55 | 0.503 |
| P value within group | 0.699 | 0.584 | |
| BMI, kg/m2 | |||
| Baseline | 27.49 ± 4.13 | 29.85 ± 4.23 | 0.021 |
| Week 12 | 27. 42 ± 4.92 | 30.89 ± 6.45 | 0.015 |
| Change | –0.11 ± 5.83 | 0.956 ± 7.44 | 0.509 |
| P value within group | 0.906 | 0.459 | |
| SBP, mmHg | |||
| Baseline | 140.92 ± 22.08 | 141.06 ± 21.61 | 0.979 |
| Week 12 | 136.08 ± 21.75 | 143.33 ± 18.98 | 0.136 |
| Change | –4.83 ± 17.73 | 2.28 ± 18.17 | 0.097 |
| P value within group | 0.11 | 0.457 | |
| DBP, mmHg | |||
| Baseline | 78.31 ± 11.18 | 77.86 ± 12.78 | 0.876 |
| Week 12 | 80.39 ± 10.88 | 80.17 ± 11.92 | 0.934 |
| Change | 2.08 ± 11.17 | 2.31 ± 13.78 | 0.940 |
| P value within group | 0.271 | 0.322 | |
| Waist circumference, cm | |||
| Baseline | 96.03 ± 8.66 | 97.63 ± 8.81 | 0.455 |
| Week 12 | 95.81 ± 8.32 | 98.25 ± 7.54 | 0.209 |
| Change | 0.68 ± 4.35 | 0.51 ± 5.58 | 0.504 |
| P value within group | 0.381 | 0.606 | |
| eGFR, mL/min/1.73m2 | |||
| Baseline | 85.98 ± 18.42 | 82.20 ± 15.87 | 0.463 |
| Week 12 | 85.105 ± 19.87 | 81.90 ± 18.07 | 0.549 |
| Change | –0.88 ± 12.0 | –0.30 ± 10.34 | 0.92 |
| P value within group | 0.699 | 0.865 |
Data are mean ± standard deviation (n). P values within groups are results of paired t test or Wilcoxon signed-rank test. P values among groups are results of independent sample t test.
Abbreviations: BMI, body mass index; DAPA, dapagliflozin; DBP: diastolic blood pressure, eGFR; estimated glomerular filtration rate SBP; systolic blood pressure.